Vax-Immune Diagnostics Takes Innovative Women's Health Diagnostic Device to European Markets to Improve Maternal Group B Strep Testing Processes
Share this article HOUSTON, Feb. 17, 2021 /PRNewswire/ -- Vax-Immune Diagnostics announces today it has received CE Mark approval for its first-in-class medical device, LabReady® GBS. LabReady's Group B Strep product is the first in Vax-Immune Diagnostics' lineup of women's health solutions that helps avoid life-threatening complications and expensive consequences for mothers and their babies. With CE Mark approval, LabReady is now available to European physicians, patients, and hospital systems. The brainchild of Dr. Leonard E. Weisman, renowned neonatologist, LabReady aims to protect...
Source: prnewswire.com